<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101129617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30409</journal-id>
<journal-id journal-id-type="nlm-ta">Genes Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Genes Brain Behav.</journal-id>
<journal-title-group>
<journal-title>Genes, brain, and behavior</journal-title>
</journal-title-group>
<issn pub-type="ppub">1601-1848</issn>
<issn pub-type="epub">1601-183X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26643147</article-id>
<article-id pub-id-type="pmc">4944654</article-id>
<article-id pub-id-type="doi">10.1111/gbb.12273</article-id>
<article-id pub-id-type="manuscript">NIHMS785357</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>RNA binding proteins, neural development and the addictions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bryant</surname>
<given-names>Camron D.</given-names>
</name>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yazdani</surname>
<given-names>Neema</given-names>
</name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label><bold>Corresponding Author</bold>, Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, 72 E. Concord St., L-606C, Boston, MA 02118, <email>camron@bu.edu</email>, P: (617) 638-4489</corresp>
<fn fn-type="conflict" id="FN1">
<p id="P43">The authors have no conflict of interests to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>7</month>
<year>2016</year>
</pub-date>
<volume>15</volume>
<issue>1</issue>
<fpage>169</fpage>
<lpage>186</lpage>
<!--elocation-id from pubmed: 10.1111/gbb.12273-->
<abstract>
<p id="P1">Transcriptional and post-transcriptional regulation of gene expression defines the neurobiological mechanisms that bridge genetic and environmental risk factors with neurobehavioral dysfunction underlying the addictions. More than 1000 genes in the eukaryotic genome code for multifunctional RNA binding proteins (RBPs) that can regulate all levels of RNA biogenesis. More than 50% of these RBPs are expressed in the brain where they regulate alternative splicing, transport, localization, stability, and translation of RNAs during development and adulthood. RBP dysfunction can exert global effects on their targetomes that underlie neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease as well as neurodevelopmental disorders, including autism and schizophrenia. Here, we consider the evidence that RBPs influence key molecular targets, neurodevelopment, synaptic plasticity, and neurobehavioral dysfunction underlying the addictions. Increasingly well-powered genome-wide association studies in humans and mammalian model organisms combined with ever more precise transcriptomic and proteomic approaches will continue to uncover novel and possibly selective roles for RBPs in the addictions. Key challenges include identifying the biological functions of the dynamic RBP targetomes from specific cell types throughout subcellular space (e.g., the nuclear spliceome versus the synaptic translatome) and time and manipulating RBP programs through post-transcriptional modifications to prevent or reverse aberrant neurodevelopment and plasticity underlying the addictions.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>